$OPTHF News

Last published 2y ago

2y agoOPTHF PBMOptimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug DevelopmentGlobeNewswireVANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical
2y agoOPTHFOptimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin CapsulesGlobeNewswireVANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive DisorderGlobeNewswireVANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP CapsulesGlobeNewswireVANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in
2y agoOPTHFOptimi Health Provides Corporate UpdateGlobeNewswireVANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics pharmaceutical
2y agoOPTHFOptimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic ResearchGlobeNewswireVANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)GlobeNewswireVANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research InstituteGlobeNewswireVANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin ExtractGlobeNewswireVANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development ConferenceGlobeNewswireVANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Health to Supply MDMA for Psychedelic Research at Tel Aviv UniversityGlobeNewswireVANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in
2y agoOPTHFOptimi Announces Closing of First Tranche of Non-Brokered Private PlacementGlobeNewswireVANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Health Canada licensed drug researcher and formulator specializing
2y agoOPTHFOptimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production VideoGlobeNewswireVANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Health Canada licensed drug researcher and formulator specializing
2y agoOPTHFOptimi Announces Non-Brokered Private PlacementGlobeNewswireVANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Health Canada licensed drug researcher and formulator specializing
2y agoOPTHFOptimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And PractitionersGlobeNewswireHighlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company's safety and quality standards.Optimi experts will address critical inquiries which still exist on the
2y agoOPTHFOptimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer's LicenceGlobeNewswireVANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Health Canada licensed drug researcher and formulator specializing
2y agoOPTHFOptimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage FormatsGlobeNewswireVANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi"), a Health Canada licensed drug researcher and formulator specializing in controlled
2y agoOPTHFOptimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply AgreementGlobeNewswireVANCOUVER, British Columbia, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi"), a licensed Canadian drug researcher and formulator specializing in controlled
2y agoOPTHFOptimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability TestingGlobeNewswireVANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a
3y agoOPTHFOptimi Health Resolves DisputeGlobeNewswireVANCOUVER, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company") is pleased to announce the successful resolution of a
3y agoOPTHFOptimi Health Welcomes Dr. Preston A. Chase as New Chief Science OfficerGlobeNewswireVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Canadian psychedelics drug research and formulation company, is delighted to announce
3y agoOPTHFOptimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt FinancingGlobeNewswireVANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi Health" or the "Company"), a Canadian drug research and formulation company licensed by
3y agoOPTHFOptimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical TrialGlobeNewswireVANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and
3y agoOPTHFOptimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access ProgramGlobeNewswireVANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that
3y agoOPTHFOptimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt FinancingGlobeNewswireVANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi Health" or the "Company"), a Canadian drug research and formulation company licensed by
3y agoOPTHFOptimi Health Announces CAD $3,000,000 Senior Debt FinancingGlobeNewswireVANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to manufacture
3y agoOPTHFOptimi Health Announces Receipt of Purported Termination NoticeGlobeNewswireVANCOUVER, British Columbia, July 27, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company") has received a termination notice and demand for payment pursuant to a
3y agoOPTHFOptimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPSGlobeNewswireVANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end drug researcher and formulator licensed by Health Canada
3y agoOPTHFOptimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical MarketGlobeNewswireVANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end drug researcher and formulator licensed by Health Canada
3y agoOPTHFOptimi Health Granted Natural Health Product Site Licence By Health CanadaGlobeNewswireVANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end drug researcher and formulator licensed by Health Canada
3y agoOPTHFOptimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and DevelopmentGlobeNewswireVANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), today announced that it has entered into a CAD$1.2 million definitive
3y agoOPTHFOptimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution AgreementGlobeNewswireHighlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using Optimi Health's MDMA
3y agoOPTHFOptimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy TherapistsGlobeNewswireVANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end Canadian-based drug manufacturer and formulator licensed
3y agoOPTHFOptimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCLGlobeNewswireThe Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi's scalable, proprietary production method. Optimi is also manufacturing MDMA under GMP-compliant protocols, making
3y agoOPTHFOptimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution AgreementsGlobeNewswireVANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end Canadian-based drug manufacturer and formulator licensed
3y agoOPTHFOptimi Health Announces Re-Appointments to Board of DirectorsGlobeNewswireVANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr.
4y agoATAI OPTHF SEEL TAK+1Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's DiseasePR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Oct. 5, 2022 /PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten approval from A
4y agoOPTHFOptimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health CanadaGlobeNewswireVANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocyb
4y agoOPTHFOptimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian HistoryGlobeNewswireVANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybi
4y agoOPTHFOptimi Health Signs First International Mushroom Supply Agreement with UK-based Avida GlobalGlobeNewswireVANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psyched
4y agoCMPS CYBN ENVB MNMD+1Psychedelics May Make People Less Afraid of DeathPR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK , Sept. 7, 2022 /PRNewswire/ -- According to a new survey by Johns Hopkins Medicine researchers, people's attitudes toward death change after a psychedelic drug experience and a non
4y agoOPTHFOptimi Health Provides Progress Report On Year Of CommercializationGlobeNewswireCompany set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Compa
4y agoATAI NUMIF OPTHF SEEL+1Psychedelics Use Among Young Adults Reaches All-Time HighPR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to 30 who
4y agoOPTHFOptimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery CenterGlobeNewswireVANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychede
4y agoOPTHFOptimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of DirectorsGlobeNewswireVANCOUVER, British Columbia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychede
4y agoOPTHFHealth Canada Grants MDMA Production and Distribution Amendment to Optimi HealthGlobeNewswireVANCOUVER, British Columbia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychede
4y agoOPTHFOptimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved PatientsGlobeNewswireBlue Serenity brings science and compassion together, will cement Thomas Hartle's legacy as a Canadian psychedelic icon Optimi and Hartle to host press conference today at 1:00 PM EST VANCOUVER, British Columbia
4y agoATAI CYBN ENVB MNMD+1Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on DepressionPR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mus
4y agoOPTHFOptimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas HartleGlobeNewswireVANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psy
4y agoOPTHFOptimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research CentreGlobeNewswireVANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functio